整块与常规经尿道膀胱肿瘤切除术:肿瘤学、组织病理学及手术结局的系统综述与Meta分析
该系统综述与Meta分析检索PubMed/Medline、Embase和Web of Science截至2024年5月的随机对照试验,比较整块膀胱肿瘤切除术(ERBT)与常规经尿道膀胱肿瘤切除术(cTURBT)。17项研究纳入分析,ERBT在12个月和24个月复发率及12个月进展率上与cTURBT无显著差异,但ERBT与更高的逼尿肌存在率、更低的膀胱穿孔和闭孔神经反射风险相关,且手术时间更长、导尿时间和住院时间更短。
要点
- ERBT与cTURBT在12个月复发(RR 0.81,95%CI 0.65-1.02;p=0.08)、24个月复发(RR 1.02,95%CI 0.85-1.22;p=0.8)和12个月进展(RR 0.68,95%CI 0.05-10.14;p=0.8)上无统计学显著差异
- ERBT与更高的逼尿肌存在率相关(RR 1.10,95%CI 1.01-1.20;p=0.02)
- ERBT与更低的膀胱穿孔风险(p=0.002)和闭孔神经反射风险(p<0.001)相关
核心结论
- ERBT因术中事件更少而更安全,但与cTURBT相比肿瘤学结局无显著差异。
- ERBT更高的逼尿肌检出率增强初始疾病分层,可能改善临床决策和诊疗服务。
研究设计与样本
- 系统综述与Meta分析,检索PubMed/Medline、Embase和Web of Science数据库,纳入截至2024年5月发表的随机对照试验,共17项研究符合纳入标准。
主要发现
- 12个月复发率:ERBT组与cTURBT组相比,RR 0.81(95%CI 0.65-1.02;p=0.08),无统计学显著差异。
- 24个月复发率:ERBT组与cTURBT组相比,RR 1.02(95%CI 0.85-1.22;p=0.8),无统计学显著差异。
- 12个月进展率:ERBT组与cTURBT组相比,RR 0.68(95%CI 0.05-10.14;p=0.8),无统计学显著差异。
- 逼尿肌存在率:ERBT组显著高于cTURBT组,RR 1.10(95%CI 1.01-1.20;p=0.02)。
- 重复经尿道膀胱肿瘤切除术(reTURBT)时残留肿瘤和黏膜肌层可检测性:ERBT组与cTURBT组相比均无统计学显著差异(均p>0.05)。
关键数值与推荐
- ERBT与更低的膀胱穿孔风险显著相关(p=0.002)。
- ERBT与更低的闭孔神经反射风险显著相关(p<0.001)。
- ERBT与更长的手术时间、更短的导尿时间和更短的住院时间显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为纳入研究间的异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: En bloc resection of bladder tumor (ERBT) has been introduced to enhance the quality of resection of bladder cancer. This review aims to compare the perioperative and oncological outcomes of ERBT and conventional transurethral resection of bladder tumor (cTURBT). METHODS: A literature search was conducted using the PubMed/Medline, Embase, and Web of Science databases to identify randomized controlled trials published until May 2024. The primary outcomes were the risk of recurrence and progression. The secondary outcomes were detrusor muscle (DM) presence, muscularis mucosae (MM) detectability, bladder perforation and obturator nerve reflex rates, operative time, length of catheterization and hospitalization, and residual tumor at repeat transurethral resection of bladder tumor (reTURBT). KEY FINDINGS AND LIMITATIONS: Seventeen studies met our inclusion criteria. No statistically significant difference was observed in 12-mo recurrence (risk ratio [RR] 0.81, 95% confidence interval [CI]: 0.65-1.02; p = 0.08), 24-mo recurrence (RR 1.02, 95% CI: 0.85-1.22; p = 0.8), and 12-mo progression (RR 0.68, 95% CI: 0.05-10.14; p = 0.8) rates. ERBT was significantly associated with a higher DM presence (RR 1.10, 95% CI: 1.01-1.20; p = 0.02), while no statistically significant difference emerged in the residual tumor at reTURBT and MM detectability (all p > 0.05). ERBT was significantly associated with a lower risk of bladder perforation (p = 0.002) and obturator nerve reflex (p < 0.001). Finally, ERBT was significantly associated with longer operative time, lower catheterization time, and lower length of hospital stay. The main limitation was heterogeneity among the included studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: ERBT is safer due to fewer intraoperative events, but there was no significant difference in oncological outcomes compared with cTURBT. Higher DM detection with ERBT enhances initial disease stratification, potentially improving clinical decision-making and care delivery. PATIENT SUMMARY: En bloc resection of bladder tumors is associated with lower intraoperative complications than and superior histopathological information to the conventional resection technique. However, the absence of a difference in oncological outcomes underscores the influence of factors such as tumor characteristics, surgeon expertise, and postoperative care on subsequent events.
引用
- Basile G, Uleri A, Leni R, et al. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-analysis of Oncological, Histopathological, and Surgical Outcomes. Eur Urol Oncol. 2024. PMID: 39428278. doi:10.1016/j.euo.2024.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。